Home › INDORAMA › Filing
🔔 Get instant alerts when INDORAMA files quarterly results on BSE Start free trial →

Investor Presentation

Filed: 23 Oct 2026, 18:25 IST Exchange: NSE Category: Financial Results — Investor Presentation
Investor Presentation - Q2FY27 - Total Income 1,344 Cr +10% y-y; EBITDA 118 Cr +47% y-y; PAT 74 Cr +202% y-y - H1 FY27 shows strong earnings momentum with Total Income 2,530.9 Cr and PAT 137.8 Cr - Specialty filament and fibre expansion plan of ~200 Cr at Butibori, operations expected CY27 - Improved utilization to 68% in FY26 from 58% in FY25; capex normalized post expansion - Strong balance sheet with ROE 38.2% and Debt to Equity 1.31x in H1 FY27 - Focus on operational efficiency, cost optimization, and product mix improvement - ESG initiatives include energy and water efficiency improvements and zero bribery cases
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 INDORAMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add INDORAMA to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Indo Rama Synthetics (India) Limited

Important. The summary above is generated automatically from Indo Rama Synthetics (India) Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.